IP Library Granted Patent US 8,242,238
Granted Patent B2
US 8,242,238 · App. 10/561,345 · Granted Aug 14, 2012

Surface protein (HBsAg) variant of the hepatitis B virus

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,242,238
App. No.
10/561,345
Granted
Aug 14, 2012
Kind
B2
Abstract

The invention relates to sequences of a novel variant of the Hepatitis B surface antigen (HBsAg) and to methods for detecting, in patient samples, nucleic acids, antigens and antibodies directed against the same.

Claims (60)

1. An isolated or purified oligopeptide or polypeptide comprising an amino acid sequence with at least 94% identity to SEQ ID NO:13 in which:

(i) from 0 to 4 amino acids are substituted, deleted, or inserted as compared with SEQ ID NO:13, and

(ii) at least one of the five amino acid substitutions in the S antigen of the hepatitis B variant HDB 05 as compared to the HBV adw wild type is preserved, wherein said substitutions are chosen from T 115 (R), P 120 (Q), S 154 (L), E 164 (V), and Q 181 (R) of the S antigen of HBV.

2. The oligopeptide or polypeptide of claim 1 , wherein the oligopeptide or polypeptide reacts with sera from individuals who are infected with the hepatitis B variant HDB 05.

3. An isolated or purified oligopeptide or polypeptide, comprising an amino acid sequence with at least 94% identity to SEQ ID NO:13 in which:

(i) from 0 to 4 amino acids are substituted, deleted or inserted as compared with SEQ ID NO:13, and

(ii) at least two of the five amino acid substitutions in the S antigen of the hepatitis B variant HDB 05 as compared to the HBV adw wild type are preserved, wherein said substitutions are chosen from T 115 (R), P 120 (Q), S 154 (L), E 164 (V), and Q 181 (R) of the S antigen of HBV.

4. The oligopeptide or polypeptide of claim 3 , wherein the oligopeptide or polypeptide reacts with sera from individuals who are infected with the hepatitis B variant HDB 05.

5. An isolated or purified oligopeptide or polypeptide comprising a fragment of SEQ ID NO:12, wherein the fragment of SEQ ID NO:12 comprises at least one of the following sequences:

(i) a sequence of at least 8 consecutive amino acids that includes amino acid position 73 of SEQ ID NO:12 and is found within positions 66-80 of SEQ ID NO:12;

(ii) a sequence of at least 6 consecutive amino acids that includes amino acid position 78 of SEQ ID NO:12 and is found within positions 73-83 of SEQ ID NO:12;

(iii) a sequence of at least 6 consecutive amino acids that includes amino acid position 112 of SEQ ID NO:12 and is found within positions 107-117 of SEQ ID NO:12;

(iv) a sequence of at least 30 consecutive amino acids that includes amino acid position 122 of SEQ ID NO:12 and is found within positions 93-151 of SEQ ID NO:12; and

(v) a sequence of at least 6 consecutive amino acids that includes amino acid position 139 of SEQ ID NO:12 and is found within positions 134-144 of SEQ ID NO:12.

6. The oligopeptide or polypeptide of claim 5 , comprising an amino acid sequence chosen from SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, and SEQ ID NO:22.

7. The oligopeptide or polypeptide of claim 5 , wherein the oligopeptide or polypeptide reacts with sera from individuals who are infected with the hepatitis B variant HDB 05.

8. A composition comprising at least one immunogenic molecule comprising one or more oligopeptides or polypeptides as claimed in one of claim 1 , 3 , 5 , or 6 , and optionally further comprising one or more HBV immunogens.

9. A method of preparing the oligopeptide or polypeptide as claimed in one of claim 1 , 3 , 5 , or 6 , which comprises culturing a cell and expressing the oligopeptide or polypeptide in said cell.

10. The method as claimed in claim 9 , wherein the oligopeptide or polypeptide is isolated from the cells and separated from other oligopeptides or polypeptides.

11. A kit for detecting hepatitis B viruses, comprising at least one of (i) an oligopeptide or polypeptide as claimed in one of claim 1 , 3 , 5 , or 6 ; (ii) an oligonucleotide or polynucleotide encoding said oligopeptide or polypeptide; and (iii) an antibody which recognizes said oligopeptide or polypeptide.

12. A method of identifying antibodies directed against a hepatitis B antigen, comprising (a) incubating a sample with an oligopeptide or polypeptide as claimed in one of claim 1 , 3 , 5 , or 6 , under conditions which allow the formation of antigen-antibody complexes; and (b) detecting antibody-antigen complexes comprising said oligopeptide or polypeptide.

13. The isolated or purified oligopeptide or polypeptide of claim 1 , wherein at least three of the five amino acid substitutions in the S antigen of the hepatitis B variant HDB 05 as compared to the HBV adw wild type are preserved, wherein said substitutions are chosen from T 115 (R), P 120 (Q), S 154 (L), E 164 (V), and Q 181 (R).

14. The isolated or purified oligopeptide or polypeptide of claim 1 , wherein at least four of the five amino acid substitutions in the S antigen of the hepatitis B variant HDB 05 as compared to the HBV adw wild type are preserved, wherein said substitutions are chosen from T 115 (R), P 120 (Q), S 154 (L), E 164 (V), and Q 181 (R).

15. The isolated or purified oligopeptide or polypeptide of claim 1 , wherein the five amino acid substitutions in the S antigen of the hepatitis B variant HDB 05 as compared to the HBV adw wild type are preserved, wherein said substitutions are chosen from T 115 (R), P 120 (Q), S 154 (L), E 164 (V), and Q 181 (R).

16. The oligopeptide or polypeptide of claim 2 , wherein the region of the amino acid sequence that reacts with the sera is chosen from at least one of the regions corresponding to amino acids 115 to 120, amino acids 154 to 164, and amino acid 154 to 185 of the S antigen of HBV.

17. The isolated or purified oligopeptide or polypeptide of claim 15 ,

wherein the oligopeptide or polypeptide reacts with sera from individuals who are infected with the hepatitis B variant HDB 05; and

wherein the region of the amino acid sequence that reacts with the sera is chosen from at least one of the regions corresponding to amino acids 115 to 120, amino acids 154 to 164, and amino acid 154 to 185 of the S antigen of HBV.

18. The isolated or purified oligopeptide or polypeptide of claim 1 ,

wherein at least two of the five amino acid substitutions in the S antigen of the hepatitis B variant HDB 05 as compared to the HBV adw wild type are preserved,

wherein said substitutions are chosen from T 115 (R), P 120 (Q), S 154 (L), E 164 (V), and Q 181 (R); and

wherein the oligopeptide or polypeptide reacts with sera from individuals who are infected with the hepatitis B variant HDB 05; and

wherein the region of the amino acid sequence that reacts with the sera is chosen from at least one of the regions corresponding to amino acids 115 to 120, amino acids 154 to 164, and amino acid 154 to 185 of the S antigen of HBV.

19. The isolated or purified oligopeptide or polypeptide of claim 5 ,

wherein the oligopeptide or polypeptide reacts with sera from individuals who are infected with the hepatitis B variant HDB 05; and

wherein the region of the amino acid sequence that reacts with the sera is chosen from at least one of the regions corresponding to amino acids 115 to 120, amino acids 154 to 164, and amino acid 154 to 185 of the S antigen of HBV.

20. An isolated or purified oligopeptide or polypeptide comprising a fragment of SEQ ID NO:12, wherein the fragment of SEQ ID NO:12 comprises at least two of the following sequences:

(i) a sequence of at least 5 consecutive amino acids that includes amino acid position 73 of SEQ ID NO:12 and is found within positions 69-77 of SEQ ID NO:12;

(ii) a sequence of at least 5 consecutive amino acids that includes amino acid position 78 of SEQ ID NO:12 and is found within positions 74-82 of SEQ ID NO:12;

(iii) a sequence of at least 5 consecutive amino acids that includes amino acid position 112 of SEQ ID NO:12 and is found within positions 108-116 of SEQ ID NO:12;

(iv) a sequence of at least 5 consecutive amino acids that includes amino acid position 122 of SEQ ID NO:12 and is found within positions 118-126 of SEQ ID NO:12; and

(v) a sequence of at least 5 consecutive amino acids that includes amino acid position 139 of SEQ ID NO:12 and is found within positions 135-143 of SEQ ID NO:12.

21. An isolated or purified oligopeptide or polypeptide comprising a fragment of SEQ ID NO:12, wherein the fragment of SEQ ID NO:12 comprises at least three of the following sequences:

(i) a sequence of at least 5 consecutive amino acids that includes amino acid position 73 of SEQ ID NO:12 and is found within positions 69-77 of SEQ ID NO:12;

(ii) a sequence of at least 5 consecutive amino acids that includes amino acid position 78 of SEQ ID NO:12 and is found within positions 74-82 of SEQ ID NO:12;

(iii) a sequence of at least 5 consecutive amino acids that includes amino acid position 112 of SEQ ID NO:12 and is found within positions 108-116 of SEQ ID NO:12;

(iv) a sequence of at least 5 consecutive amino acids that includes amino acid position 122 of SEQ ID NO:12 and is found within positions 118-126 of SEQ ID NO:12; and

(v) a sequence of at least 5 consecutive amino acids that includes amino acid position 139 of SEQ ID NO:12 and is found within positions 135-143 of SEQ ID NO:12.

22. An isolated or purified oligopeptide or polypeptide comprising a fragment of SEQ ID NO:12, wherein the fragment of SEQ ID NO:12 comprises at least four of the following sequences:

(i) a sequence of at least 5 consecutive amino acids that includes amino acid position 73 of SEQ ID NO:12 and is found within positions 69-77 of SEQ ID NO:12;

(ii) a sequence of at least 5 consecutive amino acids that includes amino acid position 78 of SEQ ID NO:12 and is found within positions 74-82 of SEQ ID NO:12;

(iii) a sequence of at least 5 consecutive amino acids that includes amino acid position 112 of SEQ ID NO:12 and is found within positions 108-116 of SEQ ID NO:12;

(iv) a sequence of at least 5 consecutive amino acids that includes amino acid position 122 of SEQ ID NO:12 and is found within positions 118-126 of SEQ ID NO:12; and

(v) a sequence of at least 5 consecutive amino acids that includes amino acid position 139 of SEQ ID NO:12 and is found within positions 135-143 of SEQ ID NO:12.

23. An isolated or purified oligopeptide or polypeptide comprising a fragment of SEQ ID NO:12, wherein the fragment of SEQ ID NO:12 comprises:

(i) a sequence of at least 5 consecutive amino acids that includes amino acid position 73 of SEQ ID NO:12 and is found within positions 69-77 of SEQ ID NO:12;

(ii) a sequence of at least 5 consecutive amino acids that includes amino acid position 78 of SEQ ID NO:12 and is found within positions 74-82 of SEQ ID NO:12;

(iii) a sequence of at least 5 consecutive amino acids that includes amino acid position 112 of SEQ ID NO:12 and is found within positions 108-116 of SEQ ID NO:12;

(iv) a sequence of at least 5 consecutive amino acids that includes amino acid position 122 of SEQ ID NO:12 and is found within positions 118-126 of SEQ ID NO:12; and

(v) a sequence of at least 5 consecutive amino acids that includes amino acid position 139 of SEQ ID NO:12 and is found within positions 135-143 of SEQ ID NO:12.

Assignments (2)
CHANGE OF NAME Recorded Feb 26, 2009
From: DADE BEHRING MARBURG GMBH
To: SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH
Reel/Frame 022309/0627 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2005
From: KRUPKA, UDO
To: DADE BEHRING MARBURG GMBH
Reel/Frame 017390/0800 →